Skip to main content

Table 6 Variables associated with the early clinical response of teicoplanin therapy in patients with complicated MRSA infections: univariate and multivariate analyses

From: Clinical efficacy and safety in patients treated with teicoplanin with a target trough concentration of 20 μg/mL using a regimen of 12 mg/kg for five doses within the initial 3 days

Factors No of patients with early clinical response (%) Univariate analysis Multivariate analysis
Patients with factor Patients without factor Crude odds ratio (95% CI) P-value Adjusted odds ratio (95%CI) P-value
Enhanced high dose loading regimen 16/23 (69.6%) 38/53 (71.7%) 0.90 (0.31–2.63) 0.851   
Teicoplanin initial Cmin ≥20 μg/mL 31/39 (79.5%) 23/37 (62.2%) 2.36 (0.09–3.95) 0.096 3.95 (1.25–12.53) 0.020
Blood stream infection 19/22 (86.4%) 33/54 (64.8%) 3.44 (0.90–13.13) 0.060 4.55 (1.10–18.77) 0.036
Respiratory infection 33/50 (66.0%) 21/26 (80.8%) 0.46 (0.15–1.44) 0.178   
Osteomyelitis and arthritis 6/9 (66.7%) 48/67 (71.6%) 0.79 (0.18–3.49) 0.713   
Central nervous system 0/1 (0.0%) 54/75 (72.0%) 0.289   
Mixed infection with Gram-negative organisms 22/34 (64.7%) 32/42 (76.2%) 0.57 (0.21–1.58) 0.272   
Therapy for definitive fungal infections 2/2 (100.0%) 52/74 (70.3%) 1.000   
Sex (male) 37/52 (71.2%) 17/24 (70.8%) 1.02 (0.35–2.95) 0.977   
Age (> 65 years) 38/57 (66.7%) 16/19 (84.2%) 0.38 (0.10–1.45) 0.144   
eGFR< 30 mL/min/1.73 m2 8/13 (61.5%) 46/63 (73.0%) 0.59 (0.17–2.06) 0.504   
Body mass index < 18.5 22/25 (88.0%) 32/51 (62.7%) 4.35 (1.15–16.52) 0.023 2.94 (0.69–12.41) 0.143
Body mass index ≥25 4/6 (66.7%) 50/70 (71.4%) 0.80 (0.14–4.72) 1.000   
Heart disease 29/37 (78.4%) 25/39 (64.1%) 2.03 (0.73–5.63) 0.170   
Chronic renal failure 11/17 (64.7%) 43/59 (72.9%) 0.68 (0.22–2.15) 0.552   
Diabetes mellitus 13/20 (65.0%) 41/56 (73.2%) 0.68 (0.23–2.03) 0.487   
Collagen disease 5/10 (50.0%) 49/66 (74.2%) 0.35 (0.09–1.35) 0.142   
Chronic respiratory disease 4/8 (50.0%) 50/68 (73.5%) 0.36 (0.08–1.59) 0.219   
Inflammatory bowel disease 7/9 (77.8%) 47/67 (70.1%) 1.49 (0.28–7.80) 1.000   
Intensive care unit stay (> 3 days) 13/22 (59.1%) 41/54 (75.9%) 0.46 (0.16–1.31) 0.142   
Liver cirrhosis/chronic hepatic dysfunction 6/12 (50.0%) 48/64 (75.0%) 0.33 (0.09–0.28) 0.094 0.28 (0.07–1.19) 0.084
Malignant tumor 23/33 (69.7%) 31/43 (72.1%) 0.89 (0.33–2.41) 0.819   
Total parenteral nutrition 10/16 (62.5%) 44/60 (73.3%) 0.61 (0.19–1.94) 0.536   
Serum albumin < 2.5 g/dL (median) 32/43 (74.4%) 22/33 (66.7%) 1.46 (0.54–3.94) 0.460   
Ventilator use 11/22 (50.0%) 43/54 (79.6%) 0.26 (0.09–0.74) 0.010 0.54 (0.16–1.86) 0.330
Surgery within 28 days 10/14 (71.4%) 44/62 (71.0%) 1.02 (0.28–3.69) 1.000   
Transplantation 2/3 (66.7%) 52/73 (71.2%) 0.81 (0.07–9.39) 1.000   
Steroid use 9/16 (56.3%) 45/60 (75.0%) 0.43 (0.14–1.35) 0.213   
Immunosuppressive therapy 2/3 (66.7%) 52/73 (71.2%) 0.81 (0.07–9.39) 1.000   
Anticancer therapy 8/12 (66.7%) 46/64 (71.9%) 0.78 (0.21–2.92) 0.736   
APACHE II score ≥ 15 17/28 (60.7%) 37/48 (77.1%) 0.46 (0.17 1.27) 0.129   
Teicoplanin-resistant MRSA (MIC ≥4 μg/mL) 0 54/76 (71.1%)   
  1. Cmin trough concentration, eGFR estimated glomerular filtration rate, APACHE II Acute physiology and chronic health evaluation II score, MIC minimum inhibitory concentration